NKTR-214 Shows Activity in Phase I RCC Study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Nektar Therapeutics presented positive phase I data for Nektar’s lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login